FDA Brief

Warning letters Food

FDA warning letter to

Penn Herb Company, Ltd.

High riskIssued Oct 19Posted Nov 10Human Foods Program

FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

What happened

FDA inspected Penn Herb's Philadelphia facility from May 12 through June 8, 2026, and reviewed product labels collected during the inspection. FDA found CGMP violations for dietary supplements, including missing specifications and unsanitary conditions, and said the company had not responded to the Form FDA 483 (inspection observations). FDA also noted that the Black Walnut Hulls label did not declare tree nuts (walnut) as a major food allergen.

What FDA found

  1. Penn Herb did not establish identity specifications for Mexican Sarsaparilla Root and Black Walnut Hulls; its checks used only appearance, color, taste and aroma, which FDA said cannot confirm species identity.

    21 CFR 111.70(b)(1)
  2. Penn Herb did not set limits for microbes and heavy metals that may contaminate Ashwagandha Root, Mexican Sarsaparilla Root and Black Walnut Hulls.

    21 CFR 111.70(b)(3)
  3. Penn Herb did not set finished-product specifications for identity, purity, strength, composition and contamination; the only listed specification was capsule weight in milligrams.

    21 CFR 111.70(e)
  4. FDA saw debris from prior runs on food-contact surfaces of the encapsulator and powder on floors, walls and ceilings, including residue after cleaning before a production run.

    21 CFR 111.360
  5. Penn Herb collected residual powder with worn tools and reused it in later production, and it could not show its sanitizer was safe for food-contact surfaces; a hand sink was out of order and opened bulk ingredient bags were taped shut with dust on exteriors.

    21 CFR 111.360
  6. The Black Walnut Hulls label declared black walnut hulls but did not declare tree nuts (walnut) as a major food allergen.

    section 403(w)(1) of the Act

What FDA wants

FDA asks Penn Herb to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If corrective actions cannot be completed in that time, the company must state why and give the expected completion time.

Who should pay attention

  • dietary supplement brands that buy botanicals from this manufacturer
  • contract manufacturers and repackagers of powdered botanicals
  • quality teams handling allergen labeling and CGMP sanitation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk